Need help from an expert
Sometimes, the medication may not work for you, or you may not be able to tolerate the full dose due to side effects, in which case, your practitioner will provide additional options or change the protocol to better suit your individual needs
For a prospectus or summary prospectus with this and other information about Roundhill ETFs please call 1-855-561-5728 or visit the website at www.roundhillinvestments.com/etf/OZEM
The cardiovascular safety profiles of GLP-1RAs are favorable, with no significant increase in the incidence of acute pancreatitis or pancreatic cancer reported.14 However, their use is associated with a higher frequency of gastrointestinal adverse events, such as nausea, vomiting, and diarrhea.15 GLP-1RAs are considered safe in patients with chronic kidney disease and effective in reducing the risk of severe hypoglycemia.16 In individuals with established cardiovascular diseases, GLP-1RAs have been shown to significantly lower the risk of major adverse cardiovascular events.15 Nevertheless, limited cardiovascular and renal outcome data for certain agents, such as oral semaglutide, have constrained their broader clinical application.17 In the context of post-transplant diabetes, GLP-1RAs exhibit efficacy and safety profiles comparable to those observed in non-transplant populations.18 This review was conducted through comprehensive searches of electronic databases, including Web of Science and PubMed, using a full-text search strategy
